OBJECTIVE:: To characterize the relationship between @entity927 ( @entity928 ) use and @entity1 outcomes in a severely injured civilian cohort, and to determine any differential effect between @entity1 who presented with and without shock. BACKGROUND:: @entity928 has demonstrated survival benefits in @entity130 @entity1 in an international randomized control trial and the military setting. The uptake of @entity928 into civilian @entity548 ( @entity548 ) has been variable. The evidence gap in mature civilian @entity130 systems is limiting the widespread use of @entity928 and its potential benefits on survival. METHODS:: Prospective cohort study of severely injured adult @entity1 (Injury severity score > 15) admitted to a civilian @entity130 system during the adoption phase of @entity928 into the hospital's MHP. Outcomes measured were mortality, @entity881 ( @entity881 ), @entity1211 , @entity281 , @entity64 , ventilator-free days (VFD), and length of stay. RESULTS:: @entity1 receiving @entity928 (n = 160, 42%) were more severely injured, shocked, and coagulopathic on arrival. @entity928 was not independently associated with any change in outcome for either the overall or nonshocked cohorts. In multivariate analysis, @entity928 was independently associated with a reduction in @entity881 [odds ratio (OR) = 0.27, confidence interval (CI): 0.10-0.73, P = 0.01] and was protective for adjusted all-cause mortality (OR = 0.16 CI: 0.03-0.86, P = 0.03) in shocked @entity1 . CONCLUSIONS:: @entity928 as part of a major @entity548 protocol within a mature civilian @entity130 system provides outcome benefits specifically for severely injured shocked @entity1 .

XXXX Use in Severely Injured Civilian @entity1 and the Effects on Outcomes: A Prospective Cohort Study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity548 :: ('MESH:D006470', 'Disease') :: ['major hemorrhage protocols', 'MHPs', 'hemorrhage'] @entity928 :: ('CHEBI:36088', 'Chemical') :: ['TXA'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infection'] @entity927 :: ('MESH:D014148', 'Chemical') :: ['tranexamic acid'] @entity881 :: ('MESH:D009102', 'Disease') :: ['MOF', 'multiple organ failure'] @entity1211 :: ('MESH:D054556', 'Disease') :: ['venous thromboembolism'] @entity130 :: ('MESH:D014947', 'Disease') :: ['trauma']
@entity927 :: (MESH:D014148,Chemical) :: ['Tranexamic Acid']
